1-18 of 18
Carolyn F. Deacon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

355-OR: Effects of a Six-Week Intervention with Glucagon-Like Peptide-1 Analogue on Pancreatic Volume, Edema, and DNA Synthesis in Obese Men

MARIA S. SVANE, HELLE H. JOHANNESEN, CHRISTOFFER MARTINUSSEN, KIRSTINE N. BOJSEN-MOLLER, MARTIN L. HANSEN, ADAM E. HANSEN, CAROLYN F. DEACON, BOLETTE HARTMANN, SUNE H. KELLER, THOMAS L. KLAUSEN, ANNIKA LOFT, ANDREAS KJAER, STEN MADSBAD, SR., JOHAN O. LÖFGREN, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN
Journal: Diabetes
Diabetes 2020;69(Supplement_1):355-OR
https://doi.org/10.2337/db20-355-OR
Published: 01 June 2020
View articletitled, 355-OR: Effects of a Six-Week Intervention with Glucagon-Like Peptide-1 Analogue on Pancreatic Volume, Edema, and DNA Synthesis in Obese Men
Journal Articles

Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes

William G. Tharp, Dhananjay Gupta, Olga Sideleva, Carolyn F. Deacon, Jens J. Holst, Dariush Elahi, Richard E. Pratley
Journal: Diabetes
Diabetes 2020;69(2):146–157
https://doi.org/10.2337/db18-1163
Published: 22 November 2019
View articletitled, Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes
Open the PDF for Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Meeting Abstracts

1002-P: Sacubitril/Valsartan Increases Postprandial Glucagon-Like Peptide-1 Concentrations and Has Synergistic Effects when Combined with Sitagliptin

NICOLAI JACOB WEWER ALBRECHTSEN, PETER DALL MARK, JR., LASSE H. HANSEN, ULRIK ØRSØ ANDERSEN, BOLETTE HARTMANN, RICHARD D. CARR, FINN GUSTAFSSON, CAROLYN F. DEACON, JENS J. HOLST, JENS PETER GØTZE, PETER PLOMGAARD
Journal: Diabetes
Diabetes 2019;68(Supplement_1):1002-P
https://doi.org/10.2337/db19-1002-P
Published: 01 June 2019
View articletitled, 1002-P: Sacubitril/Valsartan Increases Postprandial Glucagon-Like Peptide-1 Concentrations and Has Synergistic Effects when Combined with Sitagliptin
Meeting Abstracts

GLP-1 Secretion Is Increased upon Blockade of the Somatostatin Receptor Subtype 2 and 5 Resulting in GLP-1 Receptor-Mediated Lowering of Blood Glucose in Mice

SARA L. JEPSEN, NICOLAI J. WEWER ALBRECHTSEN, JENS PEDERSEN, MAJA S. ENGELSTOFT, CAROLYN F. DEACON, JENS J. HOLST
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1968-P
https://doi.org/10.2337/db18-1968-P
Published: 01 July 2018
View articletitled, GLP-1 Secretion Is Increased upon Blockade of the Somatostatin Receptor Subtype 2 and 5 Resulting in GLP-1 Receptor-Mediated Lowering of Blood Glucose in Mice
Journal Articles

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist

Michael A. Nauck, Joachim Kind, Lars D. Köthe, Jens J. Holst, Carolyn F. Deacon, Matthias Broschag, Yan Ling He, Lise Kjems, James Foley
Journal: Diabetes
Diabetes 2016;65(8):2440–2447
https://doi.org/10.2337/db16-0107
Published: 05 April 2016
View articletitled, Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist
Open the PDF for Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist in another window
Includes: Supplementary data
Journal Articles

Effects of Sitagliptin on Glycemia, Incretin Hormones, and Antropyloroduodenal Motility in Response to Intraduodenal Glucose Infusion in Healthy Lean and Obese Humans and Patients With Type 2 Diabetes Treated With or Without Metformin

Tongzhi Wu, Jing Ma, Michelle J. Bound, Helen Checklin, Carolyn F. Deacon, Karen L. Jones, Michael Horowitz, Christopher K. Rayner
Journal: Diabetes
Diabetes 2014;63(8):2776–2787
https://doi.org/10.2337/db13-1627
Published: 17 July 2014
View articletitled, Effects of Sitagliptin on Glycemia, Incretin Hormones, and Antropyloroduodenal Motility in Response to Intraduodenal Glucose Infusion in Healthy Lean and Obese Humans and Patients With Type 2 Diabetes Treated With or Without Metformin
Open the PDF for Effects of Sitagliptin on Glycemia, Incretin Hormones, and Antropyloroduodenal Motility in Response to Intraduodenal Glucose Infusion in Healthy Lean and Obese Humans and Patients With Type 2 Diabetes Treated With or Without Metformin in another window
Journal Articles

Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose

Irfan Vardarli, Elisabeth Arndt, Carolyn F. Deacon, Jens J. Holst, Michael A. Nauck
Journal: Diabetes
Diabetes 2014;63(2):663–674
https://doi.org/10.2337/db13-0805
Published: 16 January 2014
View articletitled, Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose
Open the PDF for Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose in another window
Includes: Supplementary data
Journal Articles

Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?

Carolyn F. Deacon
Journal: Diabetes
Diabetes 2012;61(9):2219–2220
https://doi.org/10.2337/db12-0649
Published: 17 August 2012
View articletitled, Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?
Open the PDF for Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes? in another window
Journal Articles

Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes

Björn A. Menge, Lena Grüber, Signe M. Jørgensen, Carolyn F. Deacon, Wolfgang E. Schmidt, Johannes D. Veldhuis, Jens J. Holst, Juris J. Meier
Journal: Diabetes
Diabetes 2011;60(8):2160–2168
https://doi.org/10.2337/db11-0251
Published: 18 July 2011
View articletitled, Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes
Open the PDF for Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes in another window
Journal Articles

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes

Nikolaos Mentis, Irfan Vardarli, Lars D. Köthe, Jens J. Holst, Carolyn F. Deacon, Michael Theodorakis, Juris J. Meier, Michael A. Nauck
Journal: Diabetes
Diabetes 2011;60(4):1270–1276
https://doi.org/10.2337/db10-1332
Published: 22 March 2011
View articletitled, GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
Open the PDF for GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes in another window
Journal Articles

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

Kristine J. Hare, Tina Vilsbøll, Meena Asmar, Carolyn F. Deacon, Filip K. Knop, Jens J. Holst
Journal: Diabetes
Diabetes 2010;59(7):1765–1770
https://doi.org/10.2337/db09-1414
Published: 01 July 2010
View articletitled, The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
Open the PDF for The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action in another window
Journal Articles

Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects

Juris J. Meier, Baptist Gallwitz, Bartholomaeus Kask, Carolyn F. Deacon, Jens J. Holst, Wolfgang E. Schmidt, Michael A. Nauck
Journal: Diabetes
Diabetes 2004;53(suppl_3):S220–S224
https://doi.org/10.2337/diabetes.53.suppl_3.S220
Published: 01 December 2004
View articletitled, Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects
Open the PDF for Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects in another window
Journal Articles

Therapeutic Strategies Based on Glucagon-Like Peptide 1

Carolyn F. Deacon
Journal: Diabetes
Diabetes 2004;53(9):2181–2189
https://doi.org/10.2337/diabetes.53.9.2181
Published: 01 September 2004
View articletitled, Therapeutic Strategies Based on Glucagon-Like Peptide 1
Open the PDF for Therapeutic Strategies Based on Glucagon-Like Peptide 1 in another window
Journal Articles

Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects

Juris J. Meier, Michael A. Nauck, Daniel Kranz, Jens J. Holst, Carolyn F. Deacon, Dirk Gaeckler, Wolfgang E. Schmidt, Baptist Gallwitz
Journal: Diabetes
Diabetes 2004;53(3):654–662
https://doi.org/10.2337/diabetes.53.3.654
Published: 01 March 2004
View articletitled, Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects
Open the PDF for Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects in another window
Journal Articles

Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes

Juris J. Meier, Katrin Hücking, Jens J. Holst, Carolyn F. Deacon, Wolff H. Schmiegel, Michael A. Nauck
Journal: Diabetes
Diabetes 2001;50(11):2497–2504
https://doi.org/10.2337/diabetes.50.11.2497
Published: 01 November 2001
View articletitled, Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes
Open the PDF for Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes in another window
Journal Articles

Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs

Carolyn F. Deacon, Patricia Danielsen, Letty Klarskov, Mette Olesen, Jens J. Holst
Journal: Diabetes
Diabetes 2001;50(7):1588–1597
https://doi.org/10.2337/diabetes.50.7.1588
Published: 01 July 2001
View articletitled, Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs
Open the PDF for Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs in another window
Journal Articles

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Tina Vilsbøll, Thure Krarup, Carolyn F. Deacon, Sten Madsbad, Jens J. Holst
Journal: Diabetes
Diabetes 2001;50(3):609–613
https://doi.org/10.2337/diabetes.50.3.609
Published: 01 March 2001
View articletitled, Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
Open the PDF for Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients in another window
Journal Articles

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

Carolyn F Deacon, Michael A Nauck, Maibritt Toft-Nielsen, Lone Pridal, Berend Willms, Jens J Holst
Journal: Diabetes
Diabetes 1995;44(9):1126–1131
https://doi.org/10.2337/diab.44.9.1126
Published: 01 September 1995
View articletitled, Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects
Open the PDF for Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects in another window